CYP19A1 and breast carcinoma: Aromatase inhibitors (AIs) are the current endocrine therapy of choice for postmenopausal women diagnosed with hormone receptor (HR)-positive breast cancer, given their superior efficacy over tamoxifen in lowering cancer recurrence.